Literature DB >> 11294515

Performance characteristics of four free phenytoin immunoassays.

W L Roberts1, T M Annesley, B K De, L Moulton, J M Juenke, T P Moyer.   

Abstract

The measurement of the unbound or free phenytoin concentration is indicated in several situations, including uremia. In patients with uremia, metabolites of phenytoin and other substances accumulate and can displace phenytoin from its protein binding sites, with a consequent increase in the free fraction of drug. Some of the phenytoin metabolites that accumulate in uremia can cross-react with phenytoin immunoassays. In this study the authors evaluated four free phenytoin immunoassays compared with a high-performance liquid chromatography (HPLC) method: the Roche COBAS Integra, the Syva EMIT 2000, the Opus INNOFLUOR, and the Abbott TDx. All four methods demonstrated good precision, with interday coefficients of variation of < or = 5% and comparable recoveries using quality control material. Two of the methods, the EMIT 2000 and COBAS Integra, showed excellent agreement with the HPLC method using samples from patients both with normal renal function and with renal insufficiency. The other two methods, the INNOFLUOR and TDx, showed average positive biases for the therapeutic range of 3-7% and 21-22%, respectively, compared with the HPLC method for samples from patients with normal renal function, and average positive biases of 24-32% and 75-81%, respectively, with samples from patients with uremia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11294515     DOI: 10.1097/00007691-200104000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Analysis of free drug fractions using near-infrared fluorescent labels and an ultrafast immunoextraction/displacement assay.

Authors:  Corey M Ohnmacht; John E Schiel; David S Hage
Journal:  Anal Chem       Date:  2006-11-01       Impact factor: 6.986

2.  Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model.

Authors:  Rob Ter Heine; Sean P Kane; Alwin D R Huitema; Matthew D Krasowski; Erik M van Maarseveen
Journal:  Br J Clin Pharmacol       Date:  2019-08-07       Impact factor: 4.335

3.  Development of a flow-based ultrafast immunoextraction and reverse displacement immunoassay: analysis of free drug fractions.

Authors:  John E Schiel; Zenghan Tong; Chainarong Sakulthaew; David S Hage
Journal:  Anal Chem       Date:  2011-11-28       Impact factor: 6.986

4.  Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations.

Authors:  Matthew D Krasowski; Louis E Penrod
Journal:  BMC Med Inform Decis Mak       Date:  2012-02-14       Impact factor: 2.796

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.